X0206 3 2017-12-07 0 0001714899 Denali Therapeutics Inc. DNLI 0001219042 NELSEN ROBERT C/O ARCH VENTURE PARTNERS 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 1 0 Common Stock 312500 I See footnote Series A-1 Preferred Stock Common Stock 10068749 I See footnote Series A-2 Preferred Stock Common Stock 375000 I See footnote Series B-1 Preferred Stock Common Stock 312500 I See footnote The shares are held of record by ARCH Venture Fund VIII, L.P., or ARCH Venture Fund VIII. The Reporting Person is a managing director of ARCH Venture Partners VIII, L.P., the general partner of ARCH Venture Fund VIII, and shares voting and investment control with respect to these shares. The Reporting Person disclaims beneficial ownership of all shares held by ARCH Venture Fund VIII except to the extent of any pecuniary interest therein. The Series A-1 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. The Series A-2 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. The Series B-1 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Exhibit 24 - Power of Attorney /s/ Tyler Nielsen, by power of attorney 2017-12-07